LILRB1 CAR-T cells offer a distinct advantage by sparing HSCs and neutrophils, potentially avoiding severe immunosuppression and providing a safer alternative to currently tested CAR-T therapies in AML. This evidence concerns the gene LILRB1 and acute myeloid leukemia.